TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36464680

Group type: EXPERIMENTAL
Intervention: Application group (APP) with information via an iPad-based application
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Doctor group (DOC) with augmented physician rounds
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination group (APP+DOC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Treatment as usual group (TAU)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: APP+DOC
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: DOC
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: APP
Number of subjects: 96

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 96
Study: 33331850

Group type: EXPERIMENTAL
Intervention: Primary intraocular lens (IOL) implantation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Aphakia (contact lens [CL])
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both treatment groups (IOL and CL)
Number of subjects: 114
Study: 33309513

Group type: EXPERIMENTAL
Intervention: FIT
Number of subjects: 14318

Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 14318
Study: 32381421

Group type: EXPERIMENTAL
Intervention: Non-invasive haemoglobin measurement (SpHb) using Radical-7®
Number of subjects: 43

Group type: COMPARATOR
Intervention: Laboratory determined haemoglobin (LabHb)
Number of subjects: 43
Study: 36418156

Group type: EXPERIMENTAL
Intervention: Evobrutinib (25 mg or 75 mg once daily, or 50 mg or 75 mg twice daily)
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Evobrutinib
Number of subjects: 1083
Study: 33565558

Group type: EXPERIMENTAL
Intervention: Probiotic group (Bifidobacterium lactis UBBLa-70, n = 10)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Symbiotic group (Bifidobacterium lactis UBBLa-70 and fructooligosaccharide, n = 11)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (placebo, n = 11)
Number of subjects: 32
Study: 32592776

Group type: EXPERIMENTAL
Intervention: Conventional white-light imaging (WLI) AI system
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Nonmagnifying narrow-band imaging (NBI) AI system
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Indigo-carmine dye contrast imaging (Indigo) AI system
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Comparison of WLI, NBI, and Indigo AI systems
Number of subjects: 1084
Study: 35483993

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Venturi mask (VM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NIV and CPAP
Number of subjects: 21
Study: 33357247

Group type: EXPERIMENTAL
Intervention: SUB dietary guidelines (DG)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: OFF dietary guidelines (DG)
Number of subjects: 219

Group type: COMPARATOR
Intervention: HAB (habitual diet)
Number of subjects: 219
Study: 35896083

Group type: EXPERIMENTAL
Intervention: Relefact LHRH® (100 μg/m2)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Addition of AEBSF to sampling tubes
Number of subjects: 13
Study: 32358357

Group type: COMPARATOR
Intervention: 12 months consolidation period (group A)
Number of subjects: 137

Group type: COMPARATOR
Intervention: 18 months consolidation period (group B)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Baseline HBeAg >1000 S/CO in group B
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Baseline ALT >133 U/L
Number of subjects: 137
Study: 35332737

Group type: EXPERIMENTAL
Intervention: Non-invasive bi-level positive airway pressure (BiPAP) ventilation in treatment group 1
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy in treatment group 2
Number of subjects: 155

Group type: COMPARATOR
Intervention: Treatment groups (1 and 2)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Treatment group 2
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Treatment group 1
Number of subjects: 155

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 155
Study: 33602198

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using laser diode 940 nm
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (no laser radiation)
Number of subjects: 25
Study: 32125257

Group type: EXPERIMENTAL
Intervention: Antiscatter grid (ASG) removal
Number of subjects: 53

Group type: COMPARATOR
Intervention: Antiscatter grid (ASG) present
Number of subjects: 53
Study: 34904689

Group type: EXPERIMENTAL
Intervention: Structured intervention for medical students
Number of subjects: 127
Study: 34413118

Group type: EXPERIMENTAL
Intervention: Insulin icodec
Number of subjects: 0

Group type: COMPARATOR
Intervention: Native human insulin (HI)
Number of subjects: 0
Study: 33253354

Group type: EXPERIMENTAL
Intervention: Verubecestat (BACE inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verubecestat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verubecestat and Placebo
Number of subjects: 0
Study: 35834528

Group type: EXPERIMENTAL
Intervention: High-dose micronutrient-antioxidant supplement
Number of subjects: 171

Group type: COMPARATOR
Intervention: RDA supplement
Number of subjects: 171
Study: 34210274

Group type: EXPERIMENTAL
Intervention: Prebiotic and protein supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) and protein supplementation
Number of subjects: 0
Study: 34996047

Group type: EXPERIMENTAL
Intervention: Resilient clinical trial infrastructure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health system resiliency framework
Number of subjects: 0
Study: 33750879

Group type: EXPERIMENTAL
Intervention: High concentrate diet feeding pattern
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intensively reared group (control)
Number of subjects: 12
Study: 35490229

Group type: EXPERIMENTAL
Intervention: Specific dietary and behavioral counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 0
Study: 32720121

Group type: EXPERIMENTAL
Intervention: NACT (Neoadjuvant Chemotherapy)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NACTRT (Neoadjuvant Chemoradiotherapy)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both NACT and NACTRT
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adjuvant RT (Radiotherapy)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nodal recurrence after RT (either neoadjuvant or adjuvant)
Number of subjects: 21
Study: 35763437

Group type: EXPERIMENTAL
Intervention: Snail secretion filtrate, Calendula officinalis, and Glycyrrhiza glaba root extract combination serum (SCGS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: SCGS with concurrent acne treatments
Number of subjects: 66

Group type: COMPARATOR
Intervention: SCGS and Placebo
Number of subjects: 66
Study: 32239958

Group type: EXPERIMENTAL
Intervention: Palladium/norbornene (Pd/NBE) catalysis under Catellani reaction conditions with lithium salts and olefins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic deuterium labeling and crossover experiments
Number of subjects: 0
Study: 35217746

Group type: EXPERIMENTAL
Intervention: Professional oral hygiene care administered every 24 hours
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Professional oral hygiene care
Number of subjects: 57
Study: 34645413

Group type: EXPERIMENTAL
Intervention: GeneSHARE (website designed to increase family communication of genetic test results)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: My Gene Counsel's Living Lab Report (digital tool designed to improve understanding of genetic test results and next steps, including CRM guidelines)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 0
Study: 34608929

Group type: EXPERIMENTAL
Intervention: Tirzepatide (1, 5, 10, 15 mg)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Dulaglutide (1.5 mg)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 33370506

Group type: EXPERIMENTAL
Intervention: Voice Therapy (VT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Selective Electrical Stimulation (SES)
Number of subjects: 51
Study: 35710241

Group type: EXPERIMENTAL
Intervention: Web-based virtual journal clubs
Number of subjects: 75

Group type: COMPARATOR
Intervention: Traditional face-to-face journal clubs
Number of subjects: 75
Study: 32577737

Group type: EXPERIMENTAL
Intervention: Resistance-band group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Biomechanical Ankle Platform System group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combination group (resistance‐band and Biomechanical Ankle Platform System)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 33608048

Group type: EXPERIMENTAL
Intervention: 12.5 mg tianeptine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 32717713

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) 100 and 200 mg/day
Number of subjects: 764

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 764
Study: 35263517

Group type: EXPERIMENTAL
Intervention: 4 months of standard first-line antituberculosis treatment
Number of subjects: 1204

Group type: COMPARATOR
Intervention: 6 months of standard first-line antituberculosis treatment
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: 4 months of treatment
Number of subjects: 1204

Group type: COMPARATOR
Intervention: 6 months of treatment
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 1204
Study: 36216945

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 34004483

Group type: EXPERIMENTAL
Intervention: Evinacumab (15 mg/kg intravenously once monthly)
Number of subjects: 2
Study: 32690063

Group type: EXPERIMENTAL
Intervention: LLIN (Long-Lasting Insecticidal Nets)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Piperonyl butoxide-treated LLIN (PBO Nets)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LLIN + IRS (Indoor Residual Spraying)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PBO Nets + LSM (Larval Source Management)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LLIN + IRS + LSM
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PBO Nets + IRS
Number of subjects: 36
Study: 36052613

Group type: EXPERIMENTAL
Intervention: Heparinized wet suction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dry suction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 50
Study: 34455435

Group type: EXPERIMENTAL
Intervention: Active oil (high-dose, purified omega-3 fatty acids) mimicking REDUCE-IT
Number of subjects: 12546

Group type: EXPERIMENTAL
Intervention: Active oil (high-dose, purified omega-3 fatty acids) mimicking STRENGTH
Number of subjects: 12546

Group type: COMPARATOR
Intervention: Comparator oil (mineral oil) mimicking REDUCE-IT
Number of subjects: 12546

Group type: COMPARATOR
Intervention: Comparator oil (corn oil) mimicking STRENGTH
Number of subjects: 12546

Group type: EXPERIMENTAL
Intervention: Active oil vs. comparator oil mimicking REDUCE-IT
Number of subjects: 12546

Group type: EXPERIMENTAL
Intervention: Active oil vs. comparator oil mimicking STRENGTH
Number of subjects: 12546
Study: 32931919

Group type: EXPERIMENTAL
Intervention: Coproduced, nurse-led intervention delivered with general practitioners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coproduced, nurse-led intervention
Number of subjects: 0
Study: 32955081

Group type: EXPERIMENTAL
Intervention: Leflunomide plus nebulized interferon alpha 2a (IFN‐α‐2a)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nebulized interferon alpha 2a (IFN‐α‐2a) alone
Number of subjects: 50
Study: 32046750

Group type: EXPERIMENTAL
Intervention: Synbiotic formula
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 180
Study: 32986470

Group type: EXPERIMENTAL
Intervention: Extended early intervention (EI)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 220
Study: 32748972

Group type: EXPERIMENTAL
Intervention: ToM training condition
Number of subjects: 210

Group type: COMPARATOR
Intervention: no-ToM training condition
Number of subjects: 210
Study: 32147182

Group type: EXPERIMENTAL
Intervention: GnRH‐a for 3 months before IVF (group A, n = 200)
Number of subjects: 400

Group type: COMPARATOR
Intervention: IVF without GnRH‐a (group B, n = 200)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Tubal factor infertility (n = 200)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: GnRH‐a for 3 months before IVF (group A)
Number of subjects: 400

Group type: COMPARATOR
Intervention: IVF without GnRH‐a (group B)
Number of subjects: 400
Study: 36131603

Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid
Number of subjects: 37
Study: 34948633

Group type: EXPERIMENTAL
Intervention: breastmilk odor + routine care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: breastmilk odor + taste + routine care
Number of subjects: 120

Group type: COMPARATOR
Intervention: routine care (gentle touch + verbal comfort)
Number of subjects: 120
Study: 35170482

Group type: EXPERIMENTAL
Intervention: Various aspects of care variables (including satisfaction with explanations, overall satisfaction with provider, learning about their medical conditions and clinician's personal manner)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 34
Study: 34656205

Group type: EXPERIMENTAL
Intervention: Immediate ComB (12 sessions)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Minimal Attention Control (MAC)
Number of subjects: 36
Study: 32204896

Group type: EXPERIMENTAL
Intervention: Individuals who declared to be donors (67.5%)
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: All individuals surveyed (90% regardless of donation status)
Number of subjects: 868
Study: 32746730

Group type: EXPERIMENTAL
Intervention: Attachment Video-feedback Intervention (AVI)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Psychoeducative intervention (PI)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Non-randomized comparison group (RS)
Number of subjects: 88
Study: 32410697

Group type: EXPERIMENTAL
Intervention: Non-surgical management (rehabilitation)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Surgical management (reconstruction)
Number of subjects: 320
Study: 35725494

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine continuous parasternal block at 7 ml/hour for 72 hours
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine continuous parasternal block
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline continuous parasternal block
Number of subjects: 45
Study: 35285173

Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg
Number of subjects: 466

Group type: COMPARATOR
Intervention: liraglutide 0.9 mg
Number of subjects: 466
Study: 35613822

Group type: EXPERIMENTAL
Intervention: Sintilimab 200 mg plus bevacizumab 15 mg/kg every 3 weeks
Number of subjects: 38
Study: 34652968

Group type: COMPARATOR
Intervention: Standard five-drug interval compressed chemotherapy (regimen A) for 17 cycles
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Experimental therapy with five cycles of vincristine, topotecan, and cyclophosphamide (VTC) within the 17 cycles (regimen B)
Number of subjects: 642
Study: 34571210

Group type: EXPERIMENTAL
Intervention: Educational video about induction of labor
Number of subjects: 119
Study: 35671133

Group type: EXPERIMENTAL
Intervention: Divided Attention (DA) + Positive Memory Reframing (PMR)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Positive Memory Reframing (PMR)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 41
Study: 32634774

Group type: EXPERIMENTAL
Intervention: Web-based educational tool
Number of subjects: 305
Study: 616896253

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 73
Study: 36088786

Group type: EXPERIMENTAL
Intervention: Drinking events with greater pre-drinking relationship harmony
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Drinking events with greater pre-drinking relationship discord
Number of subjects: 249
Study: 34227954

Group type: EXPERIMENTAL
Intervention: UNRWA clinics for physical and biochemical measurements
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Monitoring of blood pressure and blood glucose
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Participants with hypertension
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Participants with diabetes
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Participants with cardiovascular diseases (CVDs)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Participants with rheumatic diseases
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Undiagnosed hypertension
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Uncontrolled diabetes
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension
Number of subjects: 959
Study: 34606387

Group type: EXPERIMENTAL
Intervention: Self-as-Context (SAC)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal (CR)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (brochure reading)
Number of subjects: 105
Study: 32747497

Group type: EXPERIMENTAL
Intervention: BNP infusion (0.006 μg/kg/min for 72 hours)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: BNP infusion
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 33203707

Group type: EXPERIMENTAL
Intervention: Genetically predicted plasma vitamin C
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Biochemically measured plasma vitamin C
Number of subjects: 80
Study: 32629949

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention group
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention group (Greece and Spain)
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention group (Belgium and Finland)
Number of subjects: 2110
Study: 36142050

Group type: EXPERIMENTAL
Intervention: Older adults with chronic conditions
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Older adults with multimorbidities
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Older adults who are care dependent
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Older adults' HRQoL and well-being
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Gender differences in health outcomes
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Socioeconomic status (SES) impact
Number of subjects: 2399
Study: 33798307

Group type: EXPERIMENTAL
Intervention: Acupuncture at Tiaoshen acupoints (Baihui, Shenting, Yintang, Shenmen, Sanyinjiao), treated once every other day, 3 times a week for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture (non-effective point shallow acupuncture), treated once every other day, 3 times a week for 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between acupuncture and sham acupuncture groups after treatment.
Number of subjects: 60
Study: 35659393

Group type: EXPERIMENTAL
Intervention: Collaboration with artificial intelligence (AI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinician performance without AI
Number of subjects: 0
Study: 32677851

Group type: EXPERIMENTAL
Intervention: Breathing-focused yoga for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Psychoeducation for 8 weeks
Number of subjects: 72
Study: 33992032

Group type: EXPERIMENTAL
Intervention: Cementation through closure (CTC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: No tourniquet (NT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Full course (FC)
Number of subjects: 150
Study: 33883079

Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota transplantation (aFMT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 34297268

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study: 34815242

Group type: EXPERIMENTAL
Intervention: UHC Mode
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard mobile application (control)
Number of subjects: 196
Study: 35553356

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training (IMST) at 15% of PImax
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training (IMST) at 75% of PImax
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training (IMST)
Number of subjects: 7
Study: 33320286

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with simultaneous integrated boost (SIB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypofractionated RT with sequential boost (HFseq)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normofractionated RT with sequential boost (NFseq)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normofractionated RT with SIB (NFSIB)
Number of subjects: 0
Study: 33957242

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 226
Study: 32946700

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 7593

Group type: COMPARATOR
Intervention: Faecal immunochemical test (FIT)
Number of subjects: 7593
Study: 34039952

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin (belamaf)
Number of subjects: 0
Study: 35190414

Group type: EXPERIMENTAL
Intervention: SFP10‐14 intervention comprising seven weekly sessions
Number of subjects: 715

Group type: COMPARATOR
Intervention: Existing services as normal (Control)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: SFP10‐14 intervention
Number of subjects: 715
Study: 33470963

Group type: EXPERIMENTAL
Intervention: Audio-voice guided resuscitation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-guided resuscitation
Number of subjects: 20